86 related articles for article (PubMed ID: 23697247)
1. Quality of life in patients with blepharospasm.
Biuk D; Karin AA; Matić S; Barać J; Benasić T; Stiglmayer N
Coll Antropol; 2013 Mar; 37(1):29-33. PubMed ID: 23697247
[TBL] [Abstract][Full Text] [Related]
2. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years.
Streitová H; Bareš M
Acta Neurol Belg; 2014 Dec; 114(4):285-91. PubMed ID: 24604684
[TBL] [Abstract][Full Text] [Related]
3. Impact of botulinum toxin injections on quality of life and self-esteem in patients with blepharospasm.
Tang M; Li W; Ji F; Li X; Zhang Y; Liu P
Psychol Health Med; 2019 Jun; 24(5):513-518. PubMed ID: 30463432
[TBL] [Abstract][Full Text] [Related]
4. Impact on quality of life of botulinum toxin treatments for essential blepharospasm.
MacAndie K; Kemp E
Orbit; 2004 Dec; 23(4):207-10. PubMed ID: 15590520
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
Kongsengdao S; Kritalukkul S
J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm.
Ochudlo S; Bryniarski P; Opala G
Parkinsonism Relat Disord; 2007 Dec; 13(8):505-8. PubMed ID: 17543569
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in patients with blepharospasm.
Tucha O; Naumann M; Berg D; Alders GL; Lange KW
Acta Neurol Scand; 2001 Jan; 103(1):49-52. PubMed ID: 11153888
[TBL] [Abstract][Full Text] [Related]
8. Demographic and clinical features of patients with blepharospasm in southern Taiwan: a university hospital-based study.
Hwang WJ
Acta Neurol Taiwan; 2012 Sep; 21(3):108-14. PubMed ID: 23196730
[TBL] [Abstract][Full Text] [Related]
9. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression.
Müller J; Kemmler G; Wissel J; Schneider A; Voller B; Grossmann J; Diez J; Homann N; Wenning GK; Schnider P; Poewe W;
J Neurol; 2002 Jul; 249(7):842-6. PubMed ID: 12140667
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported benefit from botulinum toxin treatment for essential blepharospasm: using 2 assessment scales.
Lee RM; Chowdhury HR; Hyer JN; Smith HB; Jones CA
Ophthalmic Plast Reconstr Surg; 2013; 29(3):196-7. PubMed ID: 23446304
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
Jankovic J; Comella C; Hanschmann A; Grafe S
Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in blepharospasm or hemifacial spasm.
Reimer J; Gilg K; Karow A; Esser J; Franke GH
Acta Neurol Scand; 2005 Jan; 111(1):64-70. PubMed ID: 15595940
[TBL] [Abstract][Full Text] [Related]
13. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
Badarny S; Susel Z; Honigman S
Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
[TBL] [Abstract][Full Text] [Related]
15. Supramaximal doses of botulinum toxin for refractory blepharospasm.
Levy RL; Berman D; Parikh M; Miller NR
Ophthalmology; 2006 Sep; 113(9):1665-8. PubMed ID: 16828511
[TBL] [Abstract][Full Text] [Related]
16. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
Fezza J; Burns J; Woodward J; Truong D; Hedges T; Verma A
J Neurol Sci; 2016 Aug; 367():56-62. PubMed ID: 27423565
[TBL] [Abstract][Full Text] [Related]
17. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
Pagan FL; Harrison A
Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
[TBL] [Abstract][Full Text] [Related]
18. Blepharospasm with non-satisfactory response to treatment: our experience with IncobotulinumtoxinA.
Ricciardi L; Ialongo T; Guidubaldi A; Di Giacopo R; Bentivoglio AR
Parkinsonism Relat Disord; 2014 Jun; 20(6):665-7. PubMed ID: 24685658
[No Abstract] [Full Text] [Related]
19. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P
J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414
[TBL] [Abstract][Full Text] [Related]
20. Relationship between various clinical outcome assessments in patients with blepharospasm.
Jankovic J; Kenney C; Grafe S; Goertelmeyer R; Comes G
Mov Disord; 2009 Feb; 24(3):407-13. PubMed ID: 19053054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
